Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | GLA | P06280 | 1/20 | 0.33 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.31 |
| ▸ | TSHR | P16473 | 1/20 | 0.31 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4393687 | 0.75 | CYP3A4 (0.35) | ALDH1A1CYP3A4TSHRTDP1 | |
| SCHEMBL2103778 | 0.75 | TDP1 (0.50) | ALDH1A1CYP3A4TSHRTDP1MAPT | |
| SCHEMBL381761 | 0.74 | PTGDR2 (0.42) | KDM4EGLAPTGDR2ALDH1A1CYP3A4 | |
| SCHEMBL5454232 | 0.74 | CYP3A4 (0.42) | KDM4EALDH1A1CYP3A4TSHRTDP1 | |
| SCHEMBL5208034 | 0.71 | CYP2A6 (0.33) | KDM4EALDH1A1 | |
| SCHEMBL30788045 | 0.71 | PGR (0.49) | KDM4EGLAPTGDR2ALDH1A1CYP3A4 | |
| SCHEMBL78315 | 0.71 | PGR (0.49) | KDM4EGLAPTGDR2ALDH1A1CYP3A4 | |
| SCHEMBL4033347 | 0.69 | CD44 (0.36) | ALDH1A1CYP3A4TSHR | |
| SCHEMBL10408240 | 0.68 | KDM4E (0.36) | KDM4EGLAPTGDR2ALDH1A1MAPT | |
| SCHEMBL9983523 | 0.67 | BACE1 (0.41) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2328880-B1 | 6-SUBSTITUTED BENZOXAZINES AS 5-HT-5A RECEPTOR ANTAGONISTS | HOFFMANN LA ROCHE (CH) | 2012-10-31 | — | — | EP | disclosed |
| US-8163740-B2 | 6-substituted benzoxazines | HOFFMANN-LA ROCHE INC. (US) | 2012-04-24 | — | — | US | disclosed |
| EP-2328880-A2 | 6-SUBSTITUTED BENZOXAZINES AS 5-HT-5A RECEPTOR ANTAGONISTS | F. Hoffmann-La Roche AG (CH) | 2011-06-08 | — | — | EP | disclosed |
| WO-2010026110-A2 | 6-SUBSTITUTED BENZOXAZINES | F. HOFFMANN-LA ROCHE AG (CH) | 2010-03-11 | — | — | WO | disclosed |
| US-20100063037-A1 | 6-SUBSTITUTED BENZOXAZINES | F. HOFFMANN-LA ROCHE AG (CH) | 2010-03-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100063037-A1 | 6-SUBSTITUTED BENZOXAZINES | HTR5A, NPY5R, GABRA5 | KDM4E 944/4885GLA 1659/4885PTGDR2 204/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.